Drugs / STI-6643
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04900519 | Nov 2021 → Dec 2024 | cancer | Sorrento Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STI-6643 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04900519 ↗ |
| Route | Intravenous | “STI-6643 administered by intravenous infusion” NCT04900519 ↗ |